Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Common Equity (2016 - 2025)

Historic Common Equity for Cardiff Oncology (CRDF) over the last 16 years, with Q3 2025 value amounting to $48.8 million.

  • Cardiff Oncology's Common Equity fell 121.88% to $48.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.8 million, marking a year-over-year decrease of 121.88%. This contributed to the annual value of $82.9 million for FY2024, which is 1894.21% up from last year.
  • According to the latest figures from Q3 2025, Cardiff Oncology's Common Equity is $48.8 million, which was down 121.88% from $58.6 million recorded in Q2 2025.
  • Over the past 5 years, Cardiff Oncology's Common Equity peaked at $140.4 million during Q4 2021, and registered a low of $48.8 million during Q3 2025.
  • Over the past 5 years, Cardiff Oncology's median Common Equity value was $86.6 million (recorded in 2023), while the average stood at $92.8 million.
  • Its Common Equity has fluctuated over the past 5 years, first soared by 193171.92% in 2021, then crashed by 3949.11% in 2024.
  • Cardiff Oncology's Common Equity (Quarter) stood at $140.4 million in 2021, then decreased by 24.27% to $106.3 million in 2022, then plummeted by 34.42% to $69.7 million in 2023, then grew by 18.94% to $82.9 million in 2024, then plummeted by 41.18% to $48.8 million in 2025.
  • Its Common Equity stands at $48.8 million for Q3 2025, versus $58.6 million for Q2 2025 and $70.9 million for Q1 2025.